Avila Therapeutics
Signal active
Organization
Contact Information
Overview
Avila Therapeutics designs and develops covalent drugs for viral infections, cancers, and autoimmune diseases. It offers AVL-181, a small molecule hepatitis C virus protease inhibitor.
Avila Therapeutics has a strategic alliance with Sanofi-Aventis. The company was incorporated in 2006 and is based in Waltham, Massachusetts.
As of March 7, 2012, Avila Therapeutics operates as a subsidiary of Celgene Corporation.
About
Industries
Biotechnology, Health Care, Medical
Founded
2006
Employees
11-50
Headquarters locations
United States, North America
Social
N/A
Profile Resume
Avila Therapeutics headquartered in United States, North America, operates in the Biotechnology, Health Care, Medical sector. The company focuses on Biotechnology and has secured $3.6B in funding across 60 round(s). With a team of 11-50 employees, Avila Therapeutics is actively contributing to advancements in Biotechnology. Their latest funding round, Venture Round - Avila Therapeutics, raised $4.0M. Discover more about their projects, partnerships, and impact on our platform.
Funding Rounds
Funding rounds
5
Investors
0
Lead Investors
0
Total Funding Amount
$59.3M
Details
2
Avila Therapeutics has raised a total of $59.3M in funding over 2 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2007 | Early Stage Venture | |||
| 2009 | Early Stage Venture | 30.0M |
Investors
Avila Therapeutics is funded by 22 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Advent Venture Partners | - | FUNDING ROUND - Advent Venture Partners | 30.0M |
| Michael F. Bigham | - | FUNDING ROUND - Michael F. Bigham | 30.0M |
| Avila Therapeutics | - | FUNDING ROUND - Avila Therapeutics | 30.0M |
| Abingworth | - | FUNDING ROUND - Abingworth | 30.0M |
Recent Activity
There is no recent news or activity for this profile.